Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Lilly's Coronavirus Antibody Study Paused on Safety Concerns
by Zacks Equity Research
Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.
Gilead Sciences (GILD) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.49 in the latest trading session, marking a -0.09% move from the prior day.
Gilead & Galapagos Announce Positive Data on UC Candidate
by Zacks Equity Research
Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.
Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.
AstraZeneca's Coronavirus Antibody Therapy to Enter Late Stage
by Zacks Equity Research
AstraZeneca (AZN) plans to start two phase III studies in October for evaluating its cocktail antibody therapy for COVID-19. To this end, the company gets $486 million funding from the U.S. government.
Gilead Up on Positive Final Results for Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) gains on results from the phase III ACTT-1 study of investigational antiviral Veklury for the treatment of adults hospitalized with mild-moderate or severe COVID-19.
Stock Market News for Oct 12, 2020
by Zacks Equity Research
Wall Street closed higher on Friday buoyed by market participants' expectations for a full-phased fresh fiscal stimulus before the upcoming U.S. presidential election.
Regeneron Gains on EUA Request for Coronavirus Treatment
by Zacks Equity Research
Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.
Lilly Seeks Emergency Use of Coronavirus Antibody Candidate
by Kinjel Shah
Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.
Current Outlook Gloomy
by Zacks Equity Research
Current Outlook Gloomy
A Murky Way Forward, Plus Lilly's New Candidate
by Mark Vickery
There is plenty to address in the coming weeks and months, though not much will be moving the needle this morning.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $62.52, moving -1.7% from the previous trading session.
DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day
by Zacks Equity Research
DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day
Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia
by Kinjel Shah
After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.
Stock Market News for Oct 6, 2020
by Zacks Equity Research
Benchmarks closed higher on Monday as markets cheered news of President Trump???s positive response to Covid-19 treatment, and discharge from hospital.
Regeneron, Gilead in Focus as Trump Tests COVID-19 Positive
by Zacks Equity Research
The biotech companies experimenting coronavirus treatments are in greater focus now as President Trump test COVID-19 positive.
Sorrento & ViralClear Explore Combination Coronavirus Treatments
by Zacks Equity Research
Sorrento (SRNE) collaborates with ViralClear Pharmaceuticals to evaluate the combination of antibody and antiviral assets against COVID-19.
Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Galapagos Begins Dosing With GLPG3970 in Psoriasis Study
by Zacks Equity Research
Galapagos (GLPG) doses the first patient in an early-stage study on its Toledo compound GLPG3970 for treating psoriasis. The same is also being studied for ulcerative colitis and rheumatoid arthritis.
Regeneron Surges on Coronavirus Treatment Development Efforts
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
by Zacks Equity Research
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
Regeneron's Coronavirus Antibody Cocktail Study Data Promising
by Zacks Equity Research
Regeneron (REGN) announces encouraging initial data from its seamless phase I/II/III study, evaluating antibody cocktail candidate, REGN-COV2, in non-hospitalized patients with COVID-19.
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.